Algerian pharmaceutical company Saidal has launched a new drug called Dapaflux, aimed at managing type 2 diabetes and preventing its cardiac and kidney complications. The launch was announced during a scientific conference held in Algiers, attended by key figures including Saidal's General Director, Yunes Bouararara, and the General Secretary of the Ministry of Pharmaceutical Industry, Abdelhakim Boualdis. This development aligns with Saidal's strategy to diversify its therapeutic areas and enhance its industrial and technological capabilities.

Dapaflux is part of Saidal's efforts to expand its portfolio of treatments and improve its innovation and production capacities. The company's General Director emphasized that the launch of Dapaflux marks a significant milestone in Saidal's development, reflecting its commitment to diversifying therapeutic areas, promoting innovation, and strengthening industrial and technological capacities. He also reiterated the company's commitment to ensuring the availability of high-quality drugs at affordable prices for patients.

The launch of Dapaflux is in line with the strategic vision of the Algerian President, Abdelmadjid Tebboune, aimed at enhancing health sovereignty and improving the management of chronic diseases. According to the General Secretary of the Ministry of Pharmaceutical Industry, the ministry's approach involves adopting a comprehensive strategy for managing type 2 diabetes, focusing on early detection, regular monitoring, and prevention of cardiac and kidney complications.

The scientific conference where Dapaflux was launched brought together several experts, including professors and specialized doctors, as well as representatives from regulatory bodies. The event was an opportunity for stakeholders to discuss the latest developments in diabetes management and the role of new treatments like Dapaflux. The presence of high-level officials and experts underscores the importance of this new drug in the Algerian healthcare landscape.

Dapaflux is expected to play a crucial role in addressing the challenges posed by type 2 diabetes and its complications in Algeria. Type 2 diabetes is a significant public health concern in the country, with a growing number of patients at risk of developing serious complications. By providing a new treatment option, Saidal aims to contribute to better disease management and improved patient outcomes.

The development and launch of Dapaflux demonstrate Saidal's commitment to innovation and its role in enhancing Algeria's pharmaceutical industry. The company's efforts to diversify its therapeutic areas and strengthen its technological capabilities are seen as positive steps towards achieving its goals. The launch of Dapaflux is also expected to have a positive impact on the Algerian economy, contributing to the growth of the local pharmaceutical sector.

Moving forward, Saidal is likely to continue investing in research and development to bring new treatments to market. The company's strategy to expand its portfolio of drugs and improve its production capacities is expected to have a lasting impact on the Algerian healthcare sector. With the launch of Dapaflux, Saidal has taken a significant step towards achieving its goals and contributing to the well-being of patients in Algeria.

Key points

  • Saidal's launch of Dapaflux marks a significant milestone in its development, reflecting its commitment to diversifying therapeutic areas and strengthening industrial and technological capabilities.

Reporting sources

Share this story

Written by

SaharaWire Newsroom
SaharaWire

Reporting for SaharaWire from the Nairobi bureau.